The MEK1/2 Inhibitor ATR-002 (Zapnometinib) Synergistically Potentiates the Antiviral Effect of Direct-Acting Anti-SARS-CoV-2 Drugs
The coronavirus disease 2019 (COVID-19) represents a global public health burden. In addition to vaccination, safe and efficient antiviral treatment strategies to restrict the viral spread within the patient are urgently needed. An alternative approach to a single-drug therapy is the combinatory use...
Saved in:
Main Authors: | André Schreiber (Author), Benjamin Ambrosy (Author), Oliver Planz (Author), Sebastian Schloer (Author), Ursula Rescher (Author), Stephan Ludwig (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacokinetics, Pharmacodynamics and Antiviral Efficacy of the MEK Inhibitor Zapnometinib in Animal Models and in Humans
by: Julia Koch-Heier, et al.
Published: (2022) -
Pharmacokinetics, absorption, distribution, metabolism and excretion of the MEK inhibitor zapnometinib in rats
by: Yvonne Füll, et al.
Published: (2022) -
Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In Vitro
by: Linda Brunotte, et al.
Published: (2021) -
Repurposing Antifungals for Host-Directed Antiviral Therapy?
by: Sebastian Schloer, et al.
Published: (2022) -
Cocktail hepatocarcinoma therapy by a super-assembled nano-pill targeting XPO1 and ATR synergistically
by: Liuyun Gong, et al.
Published: (2023)